A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United States is currently investing out of its 2nd million dollar fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in the United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firm’s primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however the firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space, the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data; however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and public companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a multinational conglomerate corporation seeks to invest in disruptive early stage technologies and business model innovations. The firm looks to invest in six areas including the life science space that are strategically relevant its parent company. The firm prefers to invest in Series B round or later, but it is open to consider seed and Series A round. The firm generally allocates approximately $2 million -$5 million for early-stage companies, on a case-by-case basis. Investments are typically in forms of equity, whereas other capital structures may also be considered. The firm is seeking new investment opportunities around the globe with a focus on United States, Europe, Brazil, Singapore and China.

The firm is currently looking for new opportunities in Medical Technology, Diagnostics, Specific biotech areas and Healthcare IT. In the Medtech sector, the firm is interested in companies developing Class II Medical devices with 510(K) regulatory pathways preferably in clinic. The firm focuses on companies developing dental devices, would care, coatings and diagnostic devices. In the Biotech sector, the firm focuses on companies targeting infection prevention and food safety (such as testing and hygiene monitoring products). The firm is also interested in Healthcare IT companies developing software, solutions and platforms for better clinical and financial performance.

The firm focuses on investments in private companies. The firm considers pre-revenue companies with strong and experienced management team. The firm will take a board seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global diagnostics companies is looking to form partnerships and make investments in emerging life science companies.  The firm is highly flexible about the structure of its investments, and primarily invests in North America and Europe. The firm looks to act as a long-term, highly activist investor.

The firm primarily invests in the diagnostic imaging sector, including imaging devices and agents, CT and MR technologies, and angiography.  The firm prefers to invest in companies at or near the market approval stage but is open to considering investments in earlier-stage companies.  In addition to imaging technologies, the firm is also interested in cardiology devices, and other interventional devices including delivery devices.

The firm does not provide passive financing; the firm only invests in companies developing products that the firm would eventually market and sell.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Singapore is looking to make early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage from the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities.

The firm seeks to invest in biopharmaceuticals, diagnostics, and medical devices. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com